small molecule

NOURIANZ

ISTRADEFYLLINE

Loss of exclusivityJanuary 2028latest FDA-listed patent expiry
CompanyKyowa Kirin Co.See this company's full patent-cliff portfolio

Drug detail

Brand nameNOURIANZ
Active ingredientISTRADEFYLLINE
Strength40MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2019
Marketing statusRX

Listed patents

PatentExpiresType
7727993January 2028product
8318201September 2027product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found